Lisinopril – jeden z najwszechstronniej zbadanych inhibitorów enzymu konwertującego angiotensynę Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2015
Słowa kluczowe:
lisinopril, inhibitor enzymu konwertującego angiotensynę, nadciśnienie tętnicze, niewydolność serca, preparaty złożone
##plugins.themes.bootstrap3.article.main##
Abstrakt
Lisinopril jest jednym z najwszechstronniej zbadanych leków z grupy inhibitorów enzymu konwertującego angiotensynę. W badaniach klinicznych wykazano jego skuteczność w leczeniu nadciśnienia tętniczego, zawału mięśniasercowego, niewydolności serca oraz nefropatii i retinopatii w przebiegu nadciśnienia i/lub cukrzycy, na podstawieuzyskanych dowodów redukcji chorobowości i umieralności z przyczyn sercowo-naczyniowych oraz umieralnościogólnej w obrębie szerokiego spektrum ryzyka sercowo-naczyniowego, od nadciśnienia tętniczego do przewlekłejniewydolności serca. Połączenia lisinoprilu z hydrochlorotiazydem oraz lisinoprilu z amlodypiną, dostępne w postacipreparatów złożonych, mają wszystkie zalety, jakimi powinna się cechować kombinacja leków hipotensyjnychi mogą odgrywać ważną rolę w skojarzonym leczeniu hipotensyjnym, które jest konieczne do osiągnięcia odpowiedniejkontroli ciśnienia tętniczego u większości pacjentów z nadciśnieniem.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Jędrusik , P. (2015). Lisinopril – jeden z najwszechstronniej zbadanych inhibitorów enzymu konwertującego angiotensynę. Kardiologia W Praktyce, 9(2), 38-45. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1346
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Simpson K., Jarvis B.: Lisinopril: a review of its use in congestive heart failure. Drugs 2000; 59: 1149-1167.
2. Lisiprol – charakterystyka produktu leczniczego. Gedeon Richter Polska 2010.
3. Opie L.H.: Inhibitory konwertazy angiotensyny: postęp trwa. Via Medica, Gdańsk 2000.
4. Zannad F., Matzinger A., Larche J.: Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am. J. Hypertens. 1996; 9: 633-643.
5. Neutel J.M.: Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J. Hum. Hypertens. 2004; 18: 599-606.
6. Song J.C., White C.M.: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin. Pharmacokinet. 2002; 41: 207-224.
7. Meredith P.A., Elliott H.L.: Concentration-effect relationships and implications for trough-to-peak ratio. Am. J. Hypertens. 1996; 9: 66S-70S.
8. Martell N., Gill B., Marin R. et al.: Trough to peak ratio of once-daily lisinopril and twice-daily captopril in patients with essential hypertension. J. Hum. Hypertens. 1998; 12: 69-72.
9. Omboni S., Fogari R., Palatini P. et al.: Reproducibility and clinical value of the trough-to-peak ratio of the antihypertensive effect: evidence from the SAMPLE Study. Hypertension 1998; 32: 424-429.
10. Zannad F.: Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors? Drugs 1993; 46(supl. 2): 172-181.
11. Lancaster S.G., Todd P.A.: Lisinopril: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 35: 646-669.
12. Langtry H.D., Markham A.: Lisinopril: a review of its pharmacology and clinical efficacy in elderly patients. Drugs Aging 1997; 10: 131-166.
13. Hansson L., Lindholm L.H., Ekbom T. et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756.
14. Goa K.L., Haria M., Wilde M.I.: Lisinopril: a review of its pharmacology and use in the management of complications of diabetes mellitus. Drugs 1997; 53: 1081-1105.
15. Reisin E., Weir M.R., Falkner B. et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997; 30: 140-145.
16. Solfrizzi V., Scafato E., Frisardi V. et al.: Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age 2013; 35: 441-453.
17. Fogari R., Mugellini A., Zoppi A. et al.: Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J. Hum. Hypertens. 2006; 20: 177-185.
18. Gore P.N., Badar V.A., Hardas M.M. et al.: Comparative effects of telmisartan and lisinopril on cognitive function in metabolic syndrome patients. Int. J. Clin. Exp. Physiol. 2014; 1: 216-220.
19. Hajjar I., Hart M., Chen Y.L. et al.: Effect of Antihypertensive Therapy on Cognitive Function in Early Executive Cognitive Impairment: A Double-blind Randomized Clinical Trial. Arch. Intern. Med. 2012; 172: 442-444.
20. Agabiti-Rosei E., Muiesan M.L.: Left ventricular hypertrophy: how to influence an important risk factor in hypertension. J. Hypertens. 1998; 16(supl.): S53-S58.
21. Goa K.L., Balfour J.A., Zuanetti G.: Lisinopril: a review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs 1996; 52: 564-588.
22. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI-3). Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after myocardial infarction. Lancet 1994; 343: 1115-1122.
23. Packer M., Poole-Wilson P.A., Armstrong P.W. et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-2318.
24. Agardh C.D., Garcia-Puig J., Charbonnel B. et al.: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J. Hum. Hypertens. 1996; 10: 185-192.
25. The EUCLID study group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792.
26. Chaturvedi N., Sjolie A.K., Stephenson J.M. et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31.
27. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
28. Cushman W.C., Davis B.R., Pressel S.L. et al.: Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J. Clin. Hypertens. (Greenwich) 2012; 14: 20-31.
29. Piller L.B., Baraniuk S., Simpson L.M. et al.: Long-term follow-up of participants with heart failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation 2011; 124: 1811-1818.
30. Cushman W.C., Ford C.E., Einhorn P.T. et al.: Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J. Clin. Hypertens. (Greenwich) 2008; 10: 751-760.
31. Potter J.F., Robinson T.G., Ford G.A. et al.: Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol. 2009; 8: 48-56.
32. Shaw L., Price C., McLure S. et al.: Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST): results from the pilot randomised controlled trial. Emerg. Med. J. 2014; 31: 994-999.
33. Schrader H., Stovner L.J., Helde G. et al.: Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001; 322: 19-22.
34. Schuh-Hofer S., Flach U., Meisel A. et al.: Efficacy of lisinopril in migraine prophylaxis – an open label study. Eur. J. Neurol. 2007; 14: 701-703.
35. Paterna S., Di Pasquale P., D’Angelo A. et al.: Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. European Neurology 2000; 43: 133-136.
36. Wald D.S., Wald N.J.: Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach. J. Eval. Clin. Pract. 2012; 18: 612-615.
37. PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLoS ONE 2011; 6: e19857.
38. Soliman E.Z., Mendis S., Dissanayake W.P. et al.: A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization. Trials 2011; 12: 3.
39. The Indian Polycap Study (TIPS): Effects of a Polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomized trial. Lancet 2009, 373: 1341-1351.
40. Feldman R.D., Zou G.Y., Vandervoort M.K. et al.: A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53: 646-653.
41. Dahlof B., Sever P.S., Poulter N.R. et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
42. Jamerson K., Weber M.A., Bakris G.L. et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
43. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur. Heart J. 2013; 34: 2159-2219.
2. Lisiprol – charakterystyka produktu leczniczego. Gedeon Richter Polska 2010.
3. Opie L.H.: Inhibitory konwertazy angiotensyny: postęp trwa. Via Medica, Gdańsk 2000.
4. Zannad F., Matzinger A., Larche J.: Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am. J. Hypertens. 1996; 9: 633-643.
5. Neutel J.M.: Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J. Hum. Hypertens. 2004; 18: 599-606.
6. Song J.C., White C.M.: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin. Pharmacokinet. 2002; 41: 207-224.
7. Meredith P.A., Elliott H.L.: Concentration-effect relationships and implications for trough-to-peak ratio. Am. J. Hypertens. 1996; 9: 66S-70S.
8. Martell N., Gill B., Marin R. et al.: Trough to peak ratio of once-daily lisinopril and twice-daily captopril in patients with essential hypertension. J. Hum. Hypertens. 1998; 12: 69-72.
9. Omboni S., Fogari R., Palatini P. et al.: Reproducibility and clinical value of the trough-to-peak ratio of the antihypertensive effect: evidence from the SAMPLE Study. Hypertension 1998; 32: 424-429.
10. Zannad F.: Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors? Drugs 1993; 46(supl. 2): 172-181.
11. Lancaster S.G., Todd P.A.: Lisinopril: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 35: 646-669.
12. Langtry H.D., Markham A.: Lisinopril: a review of its pharmacology and clinical efficacy in elderly patients. Drugs Aging 1997; 10: 131-166.
13. Hansson L., Lindholm L.H., Ekbom T. et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756.
14. Goa K.L., Haria M., Wilde M.I.: Lisinopril: a review of its pharmacology and use in the management of complications of diabetes mellitus. Drugs 1997; 53: 1081-1105.
15. Reisin E., Weir M.R., Falkner B. et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997; 30: 140-145.
16. Solfrizzi V., Scafato E., Frisardi V. et al.: Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age 2013; 35: 441-453.
17. Fogari R., Mugellini A., Zoppi A. et al.: Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J. Hum. Hypertens. 2006; 20: 177-185.
18. Gore P.N., Badar V.A., Hardas M.M. et al.: Comparative effects of telmisartan and lisinopril on cognitive function in metabolic syndrome patients. Int. J. Clin. Exp. Physiol. 2014; 1: 216-220.
19. Hajjar I., Hart M., Chen Y.L. et al.: Effect of Antihypertensive Therapy on Cognitive Function in Early Executive Cognitive Impairment: A Double-blind Randomized Clinical Trial. Arch. Intern. Med. 2012; 172: 442-444.
20. Agabiti-Rosei E., Muiesan M.L.: Left ventricular hypertrophy: how to influence an important risk factor in hypertension. J. Hypertens. 1998; 16(supl.): S53-S58.
21. Goa K.L., Balfour J.A., Zuanetti G.: Lisinopril: a review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs 1996; 52: 564-588.
22. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI-3). Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after myocardial infarction. Lancet 1994; 343: 1115-1122.
23. Packer M., Poole-Wilson P.A., Armstrong P.W. et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-2318.
24. Agardh C.D., Garcia-Puig J., Charbonnel B. et al.: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J. Hum. Hypertens. 1996; 10: 185-192.
25. The EUCLID study group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792.
26. Chaturvedi N., Sjolie A.K., Stephenson J.M. et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31.
27. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
28. Cushman W.C., Davis B.R., Pressel S.L. et al.: Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J. Clin. Hypertens. (Greenwich) 2012; 14: 20-31.
29. Piller L.B., Baraniuk S., Simpson L.M. et al.: Long-term follow-up of participants with heart failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation 2011; 124: 1811-1818.
30. Cushman W.C., Ford C.E., Einhorn P.T. et al.: Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J. Clin. Hypertens. (Greenwich) 2008; 10: 751-760.
31. Potter J.F., Robinson T.G., Ford G.A. et al.: Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol. 2009; 8: 48-56.
32. Shaw L., Price C., McLure S. et al.: Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST): results from the pilot randomised controlled trial. Emerg. Med. J. 2014; 31: 994-999.
33. Schrader H., Stovner L.J., Helde G. et al.: Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001; 322: 19-22.
34. Schuh-Hofer S., Flach U., Meisel A. et al.: Efficacy of lisinopril in migraine prophylaxis – an open label study. Eur. J. Neurol. 2007; 14: 701-703.
35. Paterna S., Di Pasquale P., D’Angelo A. et al.: Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. European Neurology 2000; 43: 133-136.
36. Wald D.S., Wald N.J.: Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach. J. Eval. Clin. Pract. 2012; 18: 612-615.
37. PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLoS ONE 2011; 6: e19857.
38. Soliman E.Z., Mendis S., Dissanayake W.P. et al.: A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization. Trials 2011; 12: 3.
39. The Indian Polycap Study (TIPS): Effects of a Polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomized trial. Lancet 2009, 373: 1341-1351.
40. Feldman R.D., Zou G.Y., Vandervoort M.K. et al.: A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53: 646-653.
41. Dahlof B., Sever P.S., Poulter N.R. et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
42. Jamerson K., Weber M.A., Bakris G.L. et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
43. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur. Heart J. 2013; 34: 2159-2219.